The safety and efficacy of the biosimilar anti-CD20 antibody, Truxima, in haematological malignancy

被引：0
|
作者：
Lo, I. [1 ]
Bansal, S. [1 ]
Arami, S. [1 ]
机构：
[1] London Northwest Healthcare NHS Trust, London, England
来源：
LEUKEMIA RESEARCH | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP-48
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [21] Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma
    Grunenberg, Alexander
    Kaiser, Lisa M.
    Woelfle, Stephanie
    Schmelzle, Birgit
    Viardot, Andreas
    Moeller, Peter
    Barth, Thomas F. E.
    Muche, Rainer
    Dreyhaupt, Jens
    Buske, Christian
    FUTURE ONCOLOGY, 2020, 16 (13) : 817 - 825
  • [22] The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
    Cooper, N
    Stasi, R
    Cunningham-Rundles, SS
    Feuerstein, MA
    Leonard, JP
    Amadori, S
    Bussel, JB
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (02) : 232 - 239
  • [23] Rituximab (anti-cd20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment
    Emilia Parodi
    Bruno Nobili
    Silverio Perrotta
    Sofia Maria Rosaria Matarese
    Giovanna Russo
    Maria Licciardello
    Marco Zecca
    Franco Locatelli
    Simone Cesaro
    Gianni Bisogno
    Paola Giordano
    Domenico De Mattia
    Ugo Ramenghi
    International Journal of Hematology, 2006, 84 : 48 - 53
  • [24] Is Efficacy of the Anti-Cd20 Antibody Rituximab Preventing Hemolysis Due to Passenger Lymphocyte Syndrome?
    Tsujimura, Kazuma
    Ishida, Hideki
    Tanabe, Kazunari
    THERAPEUTIC APHERESIS AND DIALYSIS, 2017, 21 (01) : 22 - 25
  • [25] Anti-CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis
    Korhonen, Riku
    Moilanen, Eeva
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 106 (01) : 13 - 21
  • [26] What signals are generated by anti-CD20 antibody therapy?
    Bonavida B.
    Current Hematologic Malignancy Reports, 2006, 1 (4) : 205 - 213
  • [27] Obinutuzumab: a new class of anti-CD20 monoclonal antibody
    Gagez, Anne-Laure
    Cartron, Guillaume
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (05) : 484 - 491
  • [28] PC-002 (Sepantronium Bromide) Enhances the Antitumor Efficacy of Anti-CD20 Antibody By CD20 Upregulation
    Jiang, Vernon
    Li, Xiang
    He, Na
    Lv, Yan
    Wang, Haiyue
    Zhang, Ming
    Zhai, Heiyan
    Yang, Zhen
    Yang, Yi
    Guo, Dagang
    Cao, Zhixiang
    Chen, Yiyou
    BLOOD, 2024, 144 : 5822 - 5823
  • [29] Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus
    Arin, MJ
    Engert, A
    Krieg, T
    Hunzelmann, N
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 153 (03) : 620 - 625
  • [30] VELTUZUMAB Humanized Anti-CD20 Monoclonal Antibody Oncolytic
    Bhat, S. A.
    Czuczman, M. S.
    DRUGS OF THE FUTURE, 2011, 36 (07) : 519 - 526
12345